title: Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
authors.forename: Jipan
authors.initials: J
authors.lastname: Xie
authors.forename: Melissa
authors.initials: M
authors.lastname: Diener
authors.forename: Rachael
authors.initials: R
authors.lastname: Sorg
authors.forename: Eric Q
authors.initials: EQ
authors.lastname: Wu
authors.forename: Madhav
authors.initials: M
authors.lastname: Namjoshi
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000191:economics*; D050071:Bone Density Conservation Agents / Q000191:economics*; D001859:Bone Neoplasms / Q000188:drug therapy*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004164:Diphosphonates / Q000191:economics*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000191:economics*; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles